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ABSTRACT: THE ROLE OF HIPPO PATHWAY IN MITOSIS AND CANCER

Xingcheng Chen, Ph.D.
University of Nebraska, 2017
Supervisor: Jixin Dong, Ph.D.
The Hippo signaling pathway has been recently elucidated as a tumor suppressor
pathway controlling cell proliferation and apoptosis. The core of this pathway is a kinase
cascade which contains MST1/2 (Mammalian sterile 20-like kinase 1/2), LATS1/2 (large
tumor suppressor 1/2) and downstream effector named Yes-associated protein (YAP).
MST1/2 transduce their kinase activity mainly through directly phosphorylating LATS1/2.
Once phosphorylated and activated, LATS1/2 subsequently phosphorylate and inhibit
YAP from translocating to nucleus. Current studies involving the Hippo pathway focus on
determining its oncogenic role in various organs/tissues. While those studies provide
important insight into the tumor suppressor properties of this pathway, the underlying
molecular

mechanisms

through

which

the

Hippo

components

exert

their

oncogenic/suppressing function are poorly understood. Our study found that the adaptor
protein Ajuba (recent found as a positive regulator of YAP oncogenic activity) and MST2
(the core kinase in the Hippo pathway), are phosphorylated by CDK1 in mitosis via novel
sites. We further characterized the phospho-regulation of Ajuba and MST2 in mitosis and
examined the functional significance of the phosphorylation. Mutation of those
phosphorylation sites impact cell proliferation in vitro and tumorigenesis in vivo.
Our group has recently shown that the downstream effector of the Hippo pathway,
YAP, is phosphorylated during mitosis and activated in a CDK1-dependent manner. In this
study, we generated, for the first time, a doxycycline-inducible mouse model in which
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active YAP was specifically expressed in the pancreas. Interestingly, this mouse model
develops pancreatic acinar-to-ductal metaplasia (ADM) in two weeks. Moreover,
significant body weight loss and food intake decrease were observed after YAP induction
in the pancreas, which are characteristics of cachexia. Cachexia is a wasting syndrome
associated with typical types of cancer, particularly the gastrointestinal tract cancer and
lung cancer. Among those cancer types, pancreatic ductal adenocarcinoma (PDAC) has
the highest incidence of cancer cachexia. Therefore, our study suggests a potential role
of YAP in pancreatic cancer-associated cachexia (CAC).
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CHAPTER 1: AJUBA PHOSPHORYLATION BY CDK1 PROMOTES CELL
PROLIFERATION AND TUMORIGENESIS*

*The material presented in this chapter was previously published: Chen et al. J Biol Chem 2016;
291(28): 14761-14772.
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ABSTRACT
Recent studies identified the adaptor protein Ajuba as a positive regulator of Yesassociated protein (YAP) oncogenic activity through inhibiting large tumor suppressor
(Lats1/2) core kinases of the Hippo pathway, which plays important roles in cancer. In this
study, we define a novel mechanism for phospho-regulation of Ajuba in mitosis and its
biological significance in cancer. We found that Ajuba is phosphorylated in vitro and in
vivo by cyclin-dependent kinase 1 (CDK1) at Ser119 and Ser175 during the G2/M phase of
the cell cycle. Mitotic phosphorylation of Ajuba controls the expression of multiple cell
cycle regulators; however, it does not affect Hippo signaling activity, nor does it induce
epithelial-mesenchymal transition (EMT). We further showed that mitotic phosphorylation
of Ajuba is sufficient to promote cell proliferation and anchorage-independent growth in
vitro and tumorigenesis in vivo. Collectively, our discoveries reveal a previously
unrecognized mechanism for Ajuba regulation in mitosis and its role in tumorigenesis.
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1.1.

Introduction

Genetic screens in Drosophila have discovered the Hippo pathway [1] and extensive
studies have demonstrated important roles for Hippo signaling in tissue homeostasis, stem
cell function, and cancer biology [2-5]. Protein kinases MST1/2 (together with the adaptor
protein WW45) and Lats1/2 (with the regulatory subunit Mob1) form the core complexes
in the Hippo pathway and these proteins regulate each other through phosphorylation.
This core kinase signaling subsequently phosphorylates and inactivates the downstream
effectors, oncoproteins YAP and TAZ, by sequestering them in the cytoplasm and
promoting ubiquitination-dependent degradation [4, 6]. During past years, many regulators
and input signals have been identified that influence Hippo-YAP signaling activity, such
as the cell polarity and adherens junctions proteins, mechanical force, actin cytoskeleton
[6-8], hypoxia [9], energy stress [10, 11], and mitosis/cytokinesis stress [12-15]. The
downstream effectors YAP/TAZ also cross-talk with, or function as, mediators of many
other signaling pathways, such as the GPCRs, Wnt/ β-catenin, TGF-β/SMAD, EGF,
Notch, Hedgehog, and KRas/MAPK pathways [16].
A previous study identified Drosophila jub (Djub, orthologous to Ajuba proteins in
mammals) as a negative regulator of the Hippo pathway [17]. Djub promotes Yki
(Drosophila ortholog of YAP/TAZ) activation through interacting with, and inhibiting, Warts
(Drosophila ortholog of Lats1/2) kinase, and this function/mechanism appears to be
conserved in mammalian cells [17]. Subsequent studies revealed that Ajuba functions as
an adaptor protein that links EGFR-MAPK signaling to the Hippo pathway in both
Drosophila and mammals [18]. Furthermore, Djub/Ajuba are also required for JNKmediated activation of Yki/YAP, implying a conserved link between JNK signaling and
Hippo pathway [19]. Interestingly, cytoskeletal tension modulates organ growth through
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Yki in a Djub-dependent manner in Drosophila, although such a link in mammalian cells
has not been identified [20].
Ajuba family proteins, including Ajuba, LIM-domain containing protein 1 (LIMD1), and
Wilms tumor 1 interacting protein (WTIP), are adaptor/scaffold proteins with three LIM
domains at their C termini. The LIM domains interact with other proteins in various
subcellular locations to exert the biological functions of Ajuba proteins [21]. The Ajuba
family is involved in many cellular processes such as cell-cell adhesion, gene transcription,
cell proliferation, cell migration, and mitosis/cytokinesis [21]. Interestingly, several studies
also suggest that Ajuba family proteins function as potential tumor suppressors or
oncoproteins [22-26]. Some reports indicate that Ajuba is a critical member of the mitotic
machinery. For example, Ajuba activates Aurora-A kinase to recruit the CDK1-cyclin B
complex to centrosomes, and it contributes to mitotic entry [27]. Similarly, Ajuba
associates with Lats2 at centrosomes during mitosis and regulates the integrity of the
spindle apparatus [28]. Ajuba is also a microtubule-associated protein and plays a role in
metaphase-anaphase transition through interactions with Aurora-B and BubR1 at
kinetochores [29]. Collectively, these studies suggest an important role of Ajuba in mitosis,
and indicate that Ajuba may exert its oncogenic or tumor suppressive function via
dysregulation of mitosis. Ajuba has been observed to be phosphorylated by Aurora-A [27]
and Lats2 [28] in mitosis; however, the phosphorylation site(s) and its biological function
have remained elusive.
We have recently investigated how the Hippo pathway (core members and their
regulators) is regulated in mitosis. We have shown that KIBRA (an upstream regulator of
the Hippo pathway) [30, 31], YAP [12, 13], and TAZ [15] are phosphorylated by mitotic
kinases. Importantly, mitotic phosphorylation of YAP/TAZ is critical for proper mitotic
progression and for their oncogenic activity in cancer cells [12, 13, 15]. These studies
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prompted us to further examine whether other components or regulators of the Hippo
pathway are regulated by phosphorylation during mitosis. In this study, we found that
many of the Hippo members/regulators, including Ajuba, are indeed phosphorylated
during antimitotic drug-induced G2/M phase arrest. We characterized the phosphoregulation of Ajuba in mitosis, and identified CDK1 as a major kinase for mitoticphosphorylation of Ajuba. We further examined the functional significance of the
phosphorylation and found that mitotic-phosphorylation promotes the oncogenic activity
of Ajuba independently of the Hippo pathway, suggesting a novel mechanism that
regulates Ajuba in cancer cells.
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1.2.

Materials and Methods

1.2.1.

Cell Culture and Transfection

HEK293T, HEK293GP, and HeLa cell lines were purchased from American Type
Culture Collection (ATCC) and cultured as ATCC instructed. HPNE cells were provided
by Dr. Michel Ouellette (University of Nebraska Medical Center, who established and
deposited this cell line at ATCC) and were cultured as described [32].The cell lines were
authenticated at ATCC and were used at low (<25) passages. The colon cancer cell line
RCA was a gift from Dr. Michael Brattain (University of Nebraska Medical Center) [33] and
was maintained in minimal essential medium supplemented with 10% FBS and antibiotics.
Attractene (Qiagen) was used for transient overexpression of proteins in HEK293T and
HEK293GP cells following the manufacturer’s instructions. Ectopic expression of Ajuba or
its mutants in HPNE cells was achieved by a retrovirus-mediated approach. Retrovirus
packaging, infection, and subsequent selection were done as we have described
previously [34]. Nocodazole (100ng/ml for 16h) and Taxol (100 n M for 16h) (Selleck
Chemicals) were used to arrest cells in G2/M phase unless otherwise indicated. VX680
(Aurora-A,-B, and-C inhibitor), ZM447439 (Aurora-B,-C inhibitor), BI2536 (Plk1 inhibitor),
Purvalanol A (CDK1/2/5 inhibitor), SB216763 (GSK-3β inhibitor), Rapamycin (mechanistic
target of rapamycin inhibitor), and MK2206 (Akt inhibitor) were also from Selleck
Chemicals. RO3306 (CDK1 inhibitor) and Roscovitine (CDK1/2/5 inhibitor) were from
ENZO Life Sciences. MK5108 (Aurora-A inhibitor) was from Merck. Kinase inhibitors for
MEK-ERK (with U0126), p38 (with SB203580), and PI-3K (with LY294002) were from LC
Laboratory. All other chemicals were either from Sigma or ThermoFisher.
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1.2.2. Expression Constructs
The human Ajuba cDNA clone (ID HSCD00323154) was obtained from Harvard
Medical School. To make the retroviral or GFP-tagged Ajuba expression constructs, the
above full-length cDNA was cloned into the MaRXTM IV [34] or pEGFP-C1 vector
(Clontech), respectively. HA-FRMD6 (HA-EX) was made by cloning FRMD6 cDNA [35]
into the pcDNA3.1-HA vector [34]. Myc-Lats2 has been described [34]. Point mutations
were generated by the QuikChange Site-directed PCR mutagenesis kit (Stratagene) and
verified by sequencing.
1.2.3. Tet-On-inducible Expression System
Tet-On-inducible shRNA vectors against Ajuba were purchased from GE
Healthcare/Dharmacon (V3THS-343741). To make the shRNA-resistant (shR) Ajuba
cDNA, the target sequence (5’-ACCGACTACCACAAAAATT-3’) was changed into 5’ACgGAtTAtCAtAAAAATT-3’ by PCR mutagenesis. The mutated Ajuba cDNA was then
cloned into the Tet-All vector [36] to generate a Tet-On-inducible shR-Ajuba construct.
Ajuba down-regulationin RCA cells was achieved by lentivirus-mediated Ajuba shRNA
expression in a doxycycline-dependent manner. Lentivirus generation and infection were
performed as described with slight modifications [37]. The transduced cells were selected
with puromycin (1 μg/ml) to establish pooled cell lines. The cell line in which the lack of
Ajuba expression was confirmed (Tet-inducible knockdown) was then used for
transduction/infection with virus expressing Tet-All-shR Ajuba or mutant constructs. Cells
were maintained in medium containing Tet system-approved fetal bovine serum (Clontech
Laboratories).
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1.2.4. Quantitative Real-time PCR
Total RNA isolation, RNA reverse transcription, and quantitative real time-PCR were
done as we have described previously [34].Cell proliferation analysis Cell numbers were
monitored with an Invitrogen Countess automated cell counter after YAP was knocked
down or overexpressed for 5 d. Trypan blue was used to identify and quantify viable cells.
1.2.5. Recombinant Protein Purification and in Vitro Kinase Assay
The GST-tagged Ajuba (amino acids 2–240, cloned in pGEX-5X-1) proteins were
bacterially expressed and purified on GSTrap FF affinity columns (GE Healthcare)
following the manufacturer’s instructions. To make His-tagged Ajuba (amino acids 2-468),
the corresponding Ajuba cDNA was subcloned into the pET-28a vector (Novagen/EMD
Chemicals). The proteins were expressed and purified on HisPurTM Cobalt spin columns
(Pierce) following the manufacturer’s instructions.
His-or GST-Ajuba (0.5-1 μg) was incubated with 5-10 units of recombinant
CDK1/cyclin B complex (New England Biolabs) or 50-100 ng of CDK1/cyclinB
(SignalChem) or HeLa cell total lysates (treated with DMSO or Taxol) in kinase buffer
(New England Biolabs) in the presence of 5 μCi of [γ-32 P] ATP (3000 Ci/mmol,
PerkinElmer Life Sciences). Phosphorylation (32P incorporation) was visualized by
autoradiography followed by Western blotting or detected by phospho-specific antibodies.
1.2.6. Antibodies
The polyclonal Ajuba antibodies (4897) from Cell Signaling Technology were used for
Western blotting throughout the study. Rabbit polyclonal phospho-specific anti-bodies
against human Ajuba Ser119 and Ser175 were generated and purified by AbMart. The
peptides used for immunizing rabbits were TAPAL-pS-PRSSF (Ser119) and DQRHG-pS-
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PLPAG (Ser175). The corresponding non-phosphorylated peptides were also synthesized
and used for antibody purification and blocking assays. HA antibodies were from Sigma
(H9658). Anti-β-actin (SC-47778), anti-GFP (SC-9996), and anti-cyclin B (SC-752)
antibodies were from Santa Cruz Biotechnology. Aurora-A (A300-070A), glutathione Stransferase (GST) (A190-122A), His (A190-114A), MST1 (A300-465A), MST2 (A300467A), Lats1 (A300-478A), Aurora B (A300-431A), BUB1 (A300-373A), and BubR1
(A300-386A) antibodies were from Bethyl Laboratories. Phospho-Thr288 /Thr232 /Thr198
Aurora-A/B/C (2914), Phospho-Histone H3 (Ser10) (3377), phospho-Ser127 YAP (4911),
phospho-Ser909 Lats1 (9157), Lats2 (5888), WW45 (3507), TAZ (4883), TEAD1 (12292),
NF2 (6995), Vimentin (5741), E-cadherin (3195), PTPN14 (13808), LIMD1 (13245), Zyxin
(3553), CDC25C (4688), CDK1 (9116), phos-pho-Tyr15 CDK1 (9111), cyclin A (4656),
cyclin E (4132), p53 (2527), MAD2 (4636), phospho-Ser795 Rb(9301), and phospho-Ser642
Wee1 (4910) antibodies were also from Cell Signaling Technology. The monoclonal
antibody against KIBRA has been described [34]. Rabbit anti-α-tubulin (Abcam, 15246)
and mouse anti-β-tubulin (Sigma, T5293) antibodies were used for immunofluorescence
staining.
1.2.7. Phos-tag and Western Blot Analysis
Phos-tag TM was obtained from Wako Pure Chemical Industries, Ltd. (30493521) and
used at 20 μM (with 100μM MnCl2) in 6 or 8% SDS-acrylamide gels. Prior to transferring,
the gels were equilibrated in transfer buffer containing 10 m M EDTA, two times, each for
10 min. The gels were then soaked in transfer buffer (without EDTA) for another 10 min.
Western blotting, immunoprecipitation, and λ-phosphatase treatment assays were done
as previously described [31].
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1.2.8. Immunofluorescence Staining and Confocal Microscopy
Cell fixation, permeabilization, fluorescence staining, and microscopy were done as
previously described [38]. For peptide blocking, a protocol from the Abcam website was
used, as we previously described [12].
1.2.9. Colony Formation and Cell Proliferation Assays
Colony formation assays in soft agar were performed as described [32]. Cells
(10,000/well) were seeded in a 6-well plate and colonies were counted by ImageJ online.
For cell proliferation assays, cells (100,000/well) were seeded in a 6-well plate in triplicate.
Cells were counted by a hemacytometer and proliferation curves were made based on the
cell number in each well from three independent experiments.
1.2.10. Animal Studies
For in vivo xenograft studies, RCA cells (with Tet-shRNA-Ajuba) expressing Tet-AllshR-Ajuba or Tet-All-shR-Ajuba-2A (non-phosphorylatable mutant) (2.0 X 106 cells each
line) were subcutaneously injected into the left or right flank of 6-week-old male athymic
nude mice (Ncr-nu/nu, Harlan). Ten animals were used per group. Tumor sizes were
measured once a week using an electronic caliper starting at 3 weeks after injection (when
tumors in the Ajuba-2A group are palpable). Tumor volume (V) was calculated by the
formula: V = 0.5 X length X width2 [32]. Mice were euthanized at 6 weeks post-injection
and the tumors were excised for subsequent analysis. The animals were housed in
pathogen-free facilities. All animal experiments were approved by the University of
Nebraska Medical Center Institutional Animal Care and Use Committee.
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1.2.11. Statistical Analysis
Statistical significance was analyzed using a two-tailed, unpaired Student’s t test.
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1.3.

Results

1.3.1. Ajuba Family Proteins Are Phosphorylated during Antimitotic Drug-induced
G2/M Arrest
To further explore whether members of the Hippo pathway are regulated by
phosphorylation during mitosis, we examined the phosphorylation status of the Hippo
pathway proteins during G2/M arrest induced by Taxol or Nocodazole. As shown in Fig.11A, consistent with previous reports, there was a dramatic up-shift of Lats1 and Lats2
mobility (due to mitotic phosphorylation) [39] during Taxol or Nocodazole treatment (Fig.
1-1A). As expected, the mobility of KIBRA, YAP, and TAZ were all significantly retarded
due to phosphorylation during G2/M arrest (Fig. 1-1A) [12, 15, 30, 31]. Taxol or
Nocodazole treatment did not cause any evident change in the mobility/phosphorylation
for PTPN14, NF2, or EX (which are all upstream regulators of the Hippo-YAP pathway),
for WW45 or TEAD1 (Fig. 1-1A). Interestingly, MST2, but not MST1, was phosphorylated
during G2/M arrest (Fig. 1-1A). One of the most prominent changes we observed was the
striking mobility up-shift of the Ajuba and Zyxin family proteins including Ajuba, LIMD1,
and Zyxin (Fig. 1-1A). In this study, we have chosen to focus on Ajuba, and so we further
investigated its phosphorylation status. λ-Phosphatase treatment completely converted all
slow-migrating bands to fast-migrating bands, confirming that the mobility shift of Ajuba
during G2/M arrest is caused by phosphorylation (Fig. 1-1B).
1.3.2. Identification of the Corresponding Kinase for Ajuba Phosphorylation
Next, we used various kinase inhibitors to identify the candidate kinase for Ajuba
phosphorylation. In contrast to the findings in a previous study [27], our data demonstrated
that inhibition of Aurora-A (with MK5108) or Aurora-A, -B, and -C (with VX680) kinases
only mildly reduced Ajuba phosphorylation (Fig.1-1C). Addition of BI2536 (an inhibitor for
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mitotic kinase Plk1) had no effect on the Ajuba mobility shift/phosphorylation (Fig. 1-1C).
Interestingly, treatments with RO3306 (CDK1inhibitor), Roscovitine (inhibits CDK1/2/5), or
Purvalanol

A

(CDK1/2/5

inhibitor)

almost

completely

reverted

the

mobility

shift/phosphorylation (Fig. 1-1C, lanes 7-9). CDK1 is a well-known mitotic kinase. These
data suggest that CDK1 is likely the corresponding kinase for Ajuba phosphorylation
induced by Taxol or Nocodazole treatments. Inhibition of MEK-ERK kinases ( with U0126
), p38 ( with SB203580 ),GSK-3β ( with SB216763 ), mechanistic target of rapamycin (with
rapamycin), PI-3K ( with LY294002 ), or Akt ( MK2206 ) failed to alter the phosphorylation
of Ajuba during G2/M arrest (data not shown).
1.3.3. CDK1 Phosphorylates Ajuba in Vitro
To determine whether CDK1 kinase can directly phosphorylate Ajuba, we performed
in vitro kinase assays with His-tagged Ajuba proteins as substrates. Fig. 1-2A shows that
Taxol-treated mitotic lysates robustly phosphorylated Ajuba and that addition of RO3306
or Purvalanol A greatly reduced phosphorylation of His-Ajuba (Fig. 1-2A). As expected,
purified CDK1-cyclin B kinase complex phosphorylated His-Ajuba proteins in vitro (Fig. 12B). These results indicate that CDK1 directly phosphorylates Ajuba in vitro.
1.3.4. CDK1-Cyclin B Complex Phosphorylates Ajuba at Ser 119 in Vitro and in
Cells
CDK1 phosphorylates substrates at a minimal proline-directed consensus sequence
[40]. Ajuba contains a total of 6 (S/T) P motifs (Thr30, Ser119, Ser137, Ser175, Ser196,
and Ser237). Interestingly, two of them (Ser119 and Ser175) were identified as mitotic
phosphorylation sites by previous phospho-proteomic studies [41] and mutating these two
sites to alanine abolished the 32P incorporation in His-Ajuba, suggesting that Ser119 and
Ser175 are the main CDK1 sites in Ajuba in vitro (Fig. 1-2C). Ser119 and Ser175 are
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highly conserved in vertebrates (Fig. 1-2D). Therefore, these two sites were chosen for
further study.
We have generated phospho-specific antibodies against Ser119 and Ser175. In vitro
kinase assays demonstrated that CDK1 readily phosphorylates Ajuba at Ser119 (Fig. 12E). Very weak signal was detected when the phospho-Ser175 antibody was used under
these conditions (data not shown). Addition of RO3306 or mutating Ser119 to alanine
abolished the phosphorylation (Fig. 1-2E). These data suggest that CDK1 phosphorylates
Ajuba at Ser119 in vitro. Taxol treatment significantly increased the phosphorylation of
Ser119 on endogenous Ajuba (Fig. 1-2F). Using inhibitors for CDK1 kinase, we
demonstrated that phosphorylation of Ajuba Ser119 is CDK1 kinase dependent (Fig. 12F). The signal of Ajuba Ser119 during Taxol treatment was significantly reduced in Ajuba
knockdown cells, confirming the specificity of the phospho-Ser119 antibody (Fig. 1-2G).
Taxol treatment also increased the phosphorylation of Ser119 on transfected Ajuba, and
the signal was abolished by mutating Ser119 to alanine (Fig. 1-2H), suggesting that these
antibodies specifically recognize phosphorylated Ajuba. Taken together, these
observations indicate that Ajuba is phosphorylated at Ser119 by CDK1 in cells during
antimitotic drug-induced G2/M arrest.
1.3.5. CDK1/Cyclin B Mediates Ajuba Phosphorylation at Ser119 and Ser175 in
Cells
We next performed immunofluorescence microscopy with these phospho-specific
antibodies. Both antibodies against Ser119 and Ser175 detected strong signals in
Nocodazole-arrested prometaphase cells (Fig. 1-3, A-C, white arrows). The sign was
always very low or not detectable in interphase cells (Fig. 1-3, A-C, yellow arrows). The
specificity of the antibodies was further confirmed by peptide blocking assays. Phospho-
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peptide, but not control non-phosphopeptide, incubation completely blocked the signal,
suggesting that these antibodies specifically recognize Ajuba only when it is
phosphorylated (Fig. 1-3, A and B). Again, addition of RO3306 or Purvalanol A largely
diminished the signals detected by p-Ajuba Ser119 and Ser175 antibodies in Nocodazoletreated prometaphase cells, further indicating that the phosphorylation is CDK1 dependent
(Fig. 1-3, A and B, low panels).
1.3.6. Ajuba Phosphorylation Occurs during Normal Mitosis
To determine whether phosphorylation of Ajuba occurs during normal mitosis, we
collected samples from a double thymidine block and release [38] and performed
immunofluorescence staining on cells in different cell-cycle phases. Consistent with Fig.
1-3, a very weak signal was detected in interphase or cytokinesis cells (Fig. 1-4, A and B).
The p-Ajuba Ser119 signal was increased in prophase and the strongest signal was
detected in prometaphase/metaphase cells. The signal was then again weakened during
telophase (Fig. 1-4, A and B). Similar staining patterns were observed with p-Ajuba Ser175
antibody (Fig. 1-4, C and D). After being released from the double thymidine block, cells
enter into mitosis at 10-12 h revealed by increased Phospho-Histone H3 (Ser10) and the
p-Ajuba Ser119 signal was also increased in these cells (Fig. 1-4E). These results indicate
that Ajuba phosphorylation occurs dynamically during normal mitosis.
1.3.7. Mitotic Phosphorylation of Ajuba Impacts Cell Cycle Regulators without
Affecting YAP Activity
Ajuba was shown to affect the Hippo-YAP signaling activity through interacting with
Lats1/2 kinase [17-19]. We confirmed that the association between Ajuba and Lats2 was
readily detected (Fig. 1-5A). Non-phosphorylatable (Ajuba-2A, S119A/S175A) or a

16
phosphomimetic (Ajuba-2D, S119D/S175D) mutant has similar binding affinity with Lats2
as wild type Ajuba (Fig. 1-5A), suggesting that Ajuba phosphorylation does not impact its
association with Lats2. YAP Ser127 phosphorylation, Lats activity (revealed by phosphoSer909 ), and the levels of YAP and Lats proteins were not significantly altered when Ajuba
was overexpressed (in HPNE, immortalized pancreatic epithelial cells) or knocked down
(in RCA colon cancer cells) (Fig. 1-5B). Epithelial-mesenchymal transition is a critical
process during development, wound healing, and stem cell behavior, and contributes
pathologically to cancer progression and metastasis [42]. Several members of the HippoYAP signaling regulate epithelial-mesenchymal transition. However, manipulation of
Ajuba expression failed to influence the expression of the epithelial-mesenchymal
transition markers (Fig. 1-5B). In line with these observations, the targets expression of
YAP was not affected by Ajuba expression in HPNE and RCA cells (Fig. 1-5, C and D).
These results suggest that mitotic phosphorylation of Ajuba does not affect YAP activity
and that Ajuba influences Hippo-YAP activity in a context-dependent manner.
We further determined whether Ajuba/mitotic phosphorylation affects cell cycle
regulators. Interestingly, the expression of several genes (including CDC25C, BUB1 and
phosphorylated Wee1) was increased upon Ajuba knockdown in RCA cells (Fig.1-5E).
Moreover, re-expression of wild type Ajuba, but not the Ajuba-2A mutant, rescued the
phenotype (Fig. 1-5E). These observations suggest that Ajuba and its phosphorylation
may have a role in cell cycle progression through regulation of the expression of cell cycle
regulators.

17
1.3.8. Mitotic Phosphorylation of Ajuba Is Required for Cell Proliferation and
Anchorage-independent Growth
Next we asked what the biological significance of mitotic phosphorylation of Ajuba is.
To address this question, we first established HPNE cell lines stably expressing Ajuba or
non-phosphorylatable Ajuba mutant (Ajuba-2A) (Fig. 1-6A). Interestingly, overexpression
of Ajuba significantly increased cell proliferation when compared with control cells.
However, cells expressing Ajuba-2A proliferated at a rate similar to that of control cells,
suggesting that mitotic phosphorylation of Ajuba promotes cell proliferation (Fig. 1-6B).
Ectopic expression of Ajuba (wild type or 2A or 2D) was not sufficient to stimulate
anchorage-independent growth in soft agar in HPNE cells (data not shown). We further
determined the impact of mitotic phosphorylation of Ajuba in cancer cells. We established
RCA cell lines in which the endogenous Ajuba was replaced with shRNA-resistant Ajuba
or Ajuba-2A in a Tet-inducible manner (Fig. 1-6C). Without doxycycline induction, these
cell lines express similar levels of endogenous Ajuba proteins (Fig. 1-6C, left 4 lanes) and
no proliferation or other differences were detected among these cells. Addition of
doxycycline to the cell culture medium induced endogenous Ajuba knockdown and
expression of shRNA-resistant Ajuba or its non-phosphorylatable mutant (Fig. 1-6C, right
4 lanes). Consistent with the Ajuba overexpression results in HPNE cells, knockdown of
Ajuba in RCA cells decreased proliferation, and importantly, expression of wild type Ajuba,
but not the non-phosphorylatable mutant Ajuba-2A, completely rescued the cell
proliferation defects (Fig. 1-6D). Furthermore, Ajuba knockdown also significantly
decreased anchorage-independent growth in soft agar, and again, re-expression of Ajuba2A failed to rescue the defects, whereas wild type Ajuba did (Fig. 1-6, E and F). These
data suggest that mitotic phosphorylation is essential for Ajuba to promote cell proliferation
and anchorage-independent growth.
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1.3.9. Mitotic Phosphorylation of Ajuba Is Required for Tumorigenesis
We next evaluated the influence of Ajuba and its mitotic phosphorylation on tumor
growth in animals. RCA cells in which the endogenous Ajuba was replaced with shRNAresistant wild type Ajuba or Ajuba-2A (Fig. 1-6C) were subcutaneously inoculated into
immunodeficient mice. Interestingly, tumors from mice harboring Ajuba-2A-expressing
cells tended to be smaller when compared with those from mice injected with Ajubaexpressing cells (Fig. 1-7A and B). Histopathological examination revealed no significant
differences among these tumors (Fig. 1-7C). Consistent with Fig. 1-5E, CDC25C
expression was higher in Ajuba-2A-expressing tumors than Ajuba-WT tumors (Fig. 1-7C).
Western blotting analysis confirmed the phosphorylation status of Ser119, and verified that
Ajuba (wild type or 2A) expression levels were similar in most of these tumors (Fig. 1-7D).
These results support the hypothesis that mitotic phosphorylation is essential for Ajuba
promoted tumor growth in vivo.
A previous report showed that Ajuba was up-regulated in colon cancer cell lines and
tumors [22]. We further analyzed the expression of Ajuba in published data and confirmed
that the mRNA levels of Ajuba were significantly increased in colon tumors compared with
normal colon (Fig. 1-7, E–H). Together, these observations indicate that Ajuba functions
as a tumor-promoting regulator in colon cancer in a mitotic phosphorylation-dependent
manner.
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1.4.

Discussion

Ajuba family proteins (Ajuba, LIMD1, and WTIP) play roles in various cellular
processes, and one of the most studied areas is the role of Ajuba protein in mitosis. Ajuba
is required for mitotic entry in coordination with Aurora-A kinase and is co-localized at
centrosomes with Aurora-A, CDK1/cyclin B [27], and Lats2 [28] during G2/mitosis.
Interestingly, Ajuba protein became phosphorylated in mitotic cells; however, there are
differing reports regarding the kinase that contributes to this mitotic phosphorylation.
Hirota et al. [27] showed that Aurora-A directly phosphorylated Ajuba in vitro but did not
investigate whether Ajuba phosphorylation is Aurora-A dependent in cells. Another report
suggested that Lats2 contributed to Ajuba phosphorylation during mitosis [28]. The current
study provided evidence that CDK1 is the major kinase responsible for Ajuba
phosphorylation and that CDK1 phosphorylates Ajuba in vitro and in cells during mitosis,
adding a new layer of regulation for Ajuba during mitosis. Our data do not exclude the
possibility that Aurora-A and Lats2 kinases can phosphorylate Ajuba in cells as well.
Future studies are needed to further define the mitotic phosphorylation (phosphorylation
sites and their biological function) of Ajuba by Aurora-A and/or Lats2. Of note, several
large scale proteomic studies have identified Ser119 and Ser175 as mitotic phosphorylation
sites and both sites fit the CDK1-phosphorylation consensus sequence [41].
In Drosophila, Djub promotes cell proliferation and inhibits apoptosis by regulating
Hippo-Yki activity [17]. Consistent with these observations, our data further confirm that
Ajuba is a positive regulator for cell proliferation and anchorage-independent growth in
pancreatic and colon cancer cells (Fig. 1-6). Furthermore, Ajuba also promotes migration
and invasion in colon cancer cells [22]. Interestingly, whereas these studies clearly
showed that Ajuba promotes cell proliferation, Ajuba was shown to suppress malignant
mesothelioma cell proliferation [23], suggesting a cell type-specific role of Ajuba in cancer
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cells. In line with a role of Ajuba in cancer, recent large scale genomic studies found that
the Ajuba gene is mutated in 7% of esophageal squamous cell carcinomas [24, 25] and
Ajuba is overexpressed in colon cancer patients [22]. Our current study further
demonstrates that mitotic phosphorylation of Ajuba by CDK1 is critical for its biological
function, suggesting that there is a link between the role of Ajuba in cancer and its mitotic
regulation and that Ajuba may exert its role in cancer through deregulation in mitosis.
Together, these studies suggest that Ajuba may play a role in tumorigenesis, although
further confirmation will require genetic animal models. Ajuba is not essential for embryo
development and Ajuba knock-out mice have no obvious phenotypes [43]. These
observations suggest that Ajuba may function as a fine regulator in tumorigenesis and
needs an additional allele product to promote/inhibit tumor cell growth. However, knockout of the Ajuba allele has not been combined with any other oncogenes or tumor
suppressors including ones in the Hippo-YAP pathway. In addition, since there is
functional redundancy and overlapping expression within the Ajuba family proteins [21],
clearly defining the biological role of Ajuba in tumorigenesis may be even more
challenging.
Mitotic aberrations cause genomic/chromosome instability, which is characteristic of
human malignancy [44]. Several reports showed that the Hippo pathway plays important
roles in maintaining normal mitosis and suggest a mechanism through which the Hippo
tumor suppressor pathway exerts its function. For example, loss of core tumor
suppressors in the Hippo pathway (including Lats2, MST1/2, Mob1, and WW45) leads to
severe defects in multiple mitotic processes [45-47]. Accordingly, we recently reported that
overexpression of active YAP [12, 13] or TAZ [15] is sufficient to trigger mitotic defects,
including centrosome amplification, spindle disorganization, chromosome misalignment,
and subsequent aneuploidy. Interestingly, we also found that several Hippo core members
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(Lats1, Lats2, and MST2) (Fig. 1-1) or their upstream regulator (KIBRA) [30, 31] or
downstream effectors ( YAP and TAZ ) [12, 13, 15] are phosphorylated during mitosis.
Importantly, mitotic phosphorylation is critical for their oncogenic or tumor suppressive
functions [12, 13, 15]. These observations suggest that in addition to their expression
levels, the phosphorylation status of these proteins must also be finely controlled, adding
another layer of regulation for Hippo-YAP activity during tumorigenesis. Such studies may
provide additional insights into the underlying mechanisms of Hippo-YAP signaling in
cancer. Thus, we extended our studies to other Hippo regulators and we found that the
Ajuba/Zyxin family proteins (Ajuba, LIMD1, and Zyxin) are also phosphorylated during
antimitotic drug-induced mitotic arrest (Fig. 1-1). Zxyin was previously shown to be
phosphorylated and played a role in mitosis; however, the phosphorylation sites,
corresponding kinase, and their functional significance remain elusive [48]. Although these
proteins are structurally and functionally related, sites analogous to Ajuba Ser119 and
Ser175 do not exist on LIMD1 and Zyxin. Additionally, the role of LIMD1 and its regulation
in mitosis also remain to be defined. Addressing these questions will not only help
understand the cellular function of these proteins in mitosis, but also provide insights into
their biological significance and underlying mechanisms in cancer development.
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Figure 1-1. CDK1-dependent phosphorylation of Ajuba during G2/M arrest.
(A) HeLa cells were treated with DMSO, Taxol (100 nM for 16 h), or Nocodazole (Noco,
100 ng/ml for 16h). Total cell lysates were probed with the indicated antibodies against
Hippo

components

on

Phos-tag

SDS-polyacrylamide

gels

(see

“Experimental

Procedures”). O and * mark the non-phosphorylated and phosphorylated proteins,
respectively. (B) HeLa cells were treated with Taxol as indicated and cell lysates were
further treated with (+) or without (-) λ-phosphatase (ppase). Total cell lysates were probed
with anti-Ajuba antibody. (C) HeLa cells were treated with Taxol together with or without
various kinase inhibitors as indicated. VX680 (2 μM ), MK5108 (10 μM ), ZM447439(1
μM ), RO3306( 5 μM ), Roscovitine (30 μM ), Purvalanol A ( 10 μM ), and BI2536 (100
nM ) were used. Inhibitors were added (with MG132 to prevent cyclin B from degradation
and cells from exiting from mitosis) 1 - 2 h before harvesting the cells. Total cell lysates
were subjected to Western blotting with the indicated antibodies.
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Figure 1-2. Ajuba is phosphorylated by CDK1 in vitro and in cells
(A) In vitro kinase assays using HeLa cell lysates to phosphorylate recombinant His-Ajuba.
Asy,asynchronized; Tax, Taxol-treated. Total cell lysates were probed with cyclin B and
β-actin antibodies. RO3306 (5 μM) or PurvalanolA (10 μM) was used to inhibit CDK1
kinase activity. (B) In vitro kinase assays with purified CDK1/cyclin B complex. RO3306 (5
μM) was used to inhibit CDK1 kinase activity. (C) In vitro kinase assays with purified
CDK1/cyclin B complex. 2A, S119A/S175A. (D) Conservation of the mitotic
phosphorylation sites of Ajuba. (E) In vitro kinase assays were done as in B except antiphospho-Ajuba Ser119 antibodies were used. (F) HeLa cells were treated with Taxol
together with or without various kinase inhibitors as indicated. Inhibitors were added (with
MG132 to prevent cyclin B from degradation and cells from exiting from mitosis) 1h before
harvesting the cells. Total cell lysates were subjected to Western blotting with the indicated
antibodies. (G) RKO colon cancer cells expressing Tet-control shRNA or Tet-shRNA
Ajuba ( #1 and #2 ) in the presence of doxycycline (1μg/ml for 2 days ) were treated with
(+) or without (-) Taxol and total cell lysates were subjected to Western blotting with the
indicated antibodies. (H) HEK293T cells were transfected with GFP-Ajuba or GFP-Ajuba
mutants. At 32h post-transfection, the cells were treated with Taxol for 16 h. The
immunoprecipitates (with GFP antibodies) were probed with anti-phospho-Ajuba and
subsequent anti-GFP antibodies. Total cell lysates before immunoprecipitation were also
included (cyclin B and β-actin).
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Figure 1-3. CDK1 mediates the phosphorylation of Ajuba at Ser119 and Ser175 during
G2/M phase arrest.
(A) HeLa cells were treated with Nocodazole for 8h and then fixed. Before the cells were
stained with phospho-specific antibody against Ser119 of Ajuba, the cells were preincubated with PBS (no peptide control), or non-phosphorylated (control) peptide, or the
phosphorylated peptide used for immunizing rabbits. CDK1 inhibitors RO3306 (5μM) or
Purvalanol A (10μM) together with MG132 (25 μM) were added 2 h before the cells were
fixed (bottom two rows). (B) Experiments were done similarly as in A with phospho-specific
antibody against Ser175 of Ajuba. (C) HeLa cells were treated and stained with phosphospecific antibodies as in A and B. An X63 oil objective lens was used to view fewer cells
in a field. P-H3 S10 was used as a mitotic marker. White and yellow arrows mark some of
the prometaphase cells and the interphase cells, respectively.
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Figure 1-4. Ajuba is phosphorylated at Ser119 and Ser175 during unperturbed mitosis.
(A-B) HeLa cells were synchronized by a double thymidine (DT) block and release
method. Cells were stained with antibodies against p-Ajuba Ser119 or β-tubulin, or with
DAPI. An X40 objective lens was used to view various phases of the cells in a field (B).
(C-D) The experiments were done similarly as in A and B with p-Ajuba Ser175 antibodies.
White and yellow arrows (in panels B and D) mark the metaphase and interphase cells,
respectively. (E) HeLa cells were synchronized by a double thymidine block and release
method. Total cell lysates were harvested at the indicated time points and subjected to
Western blotting analysis.
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Figure 1-5. Mitotic phosphorylation controls the expression of cell cycle regulators,
but does not affect the Hippo-YAP activity.
(A) HEK293T cells were transfected with various DNA plasmids as indicated. The
immunoprecipitates (with Myc antibodies) were probed with anti-Ajuba and subsequent
anti-Myc antibodies. Total cell lysates before immunoprecipitation were also included
(Input). (B) Total cell lysates from various HPNE and RCA cell lines as indicated were
probed with the indicated antibodies. HPNE cells were stably transduced with vector,
Ajuba, Ajuba-2A, or Ajuba-2D. Tet-On-inducible Ajuba-knockdown cell lines expressing
shRNA-resistant Ajuba or Ajuba-2A in RCA colon cancer cells were also established (see
“Experimental Procedures“). 2A, S119A/S175A; 2D, S119D/S175D. (C-D) Quantitative
RT-PCR for CTGF and Cyr61 in cell lines established in B. (E) Total cell lysates were
harvested from RCA cell lines established in B and were subjected to Western blotting
analysis with various cell cycle regulators.
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Figure 1-6. Mitotic phosphorylation of Ajuba is required for cell proliferation and
anchorage-independent growth.
(A) HPNE cells stably expressing vector, Ajuba, or Ajuba-2A were established, and
expression of Ajuba and Ajunba-2A were confirmed by Western blotting. 2A, S119A/S175
A. (B) Cell proliferation assays with transduced HPNE cells established in A. Data were
expressed as the mean ± S.D. of three independent experiments. ***, p<0.001;*, p<0.05
(Ajuba-WT versus Ajuba-2A) (t test). (C) Establishment of Tet-On-inducible Ajubaknockdown cell lines expressing shRNA-resistant Ajuba or Ajuba-2A in RCA colon cancer
cells (see “Materials and Methods“). Cells were kept on Tet-approved FBS and
doxycycline was added (1 μg/ml) to the cells 2 days prior to the experiments. (D) Cell
proliferation assays in RCA cells established in C in the presence of doxycycline (DOX).
Data were expressed as the mean ± S.D. of three independent experiments. Red asterisks
mark the comparisons between shControl and shAjuba. Green asterisks indicate the
comparisons between Tet-Ajuba-WT and Tet-Ajuba-2A. ***, p<0.001;**, p<0.01;*, p<0.05
(t test). (E-F), colony assays in soft agar to assess anchorage-independent growth of RCA
cells established in C in the presence of doxycycline. Data were expressed as the mean
± S.D. of three repeats (E) and representative images were shown (F). ***, p<0.001;**, p
<0.01 (t test).

33

34
Figure 1-7. Ajuba phosphorylation is essential for tumorigenesis in mice.
(A) Tumor growth curve. RCA cells expressing Tet-shRNA Ajuba and shRNA-resistant
wild type Ajuba or Ajuba-2A were subcutaneously inoculated into athymic nude mice
(Ajuba-WT on the left flank and Ajuba-2A on the right flank) and the mice were kept on
doxycycline (0.5mg/ml) in their drinking water throughout the experiment. Two of ten mice
did not form visible tumors (both left and right sides) and were excluded from the analysis.
Therefore, the tumor volume at each point was the average of 8 tumors. The p values are
also shown. **, p<0.01;*, p<0.05 (t test). (B) The largest four tumors in each group were
excised and photographed at the endpoint. C, hematoxylin and eosin (H&E) and CDC25C
IHC staining in tumors shown in B. (D) Western blotting analysis with tumor samples from
B. (E-H) The mRNA levels of Ajuba in normal colon and colon tumors from public data
sets. Data were mined from Oncomine.org. The original studies were as follows: Refs.
[49](E), [50](F), [51](G), and [52] (H).Tumors, colorectal carcinoma; CA, colorectal
adenocarcinoma.
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CHAPTER 2: MST2 PHOSPHORYLATION AT SERINE 385 IN MITOSIS
INHIBITS ITS TUMOR SUPPRESSING ACTIVITY*

*

The material presented in this chapter was previously published: Chen et al. Cell Signal
2016; 28(12): 1826-1832.
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ABSTRACT
Mammalian sterile 20-like kinase 1/2 (MST1/2) are core tumor suppressors in the
Hippo signaling pathway. MST1/2 have been shown to regulate mitotic progression. Here,
we report a novel mechanism for phospho-regulation of MST2 in mitosis and its biological
significance in cancer. We found that the mitotic kinase cyclin-dependent kinase 1 (CDK1)
phosphorylates MST2 in vitro and in vivo at serine 385 during antimitotic drug-induced
G2/M phase arrest. This phosphorylation occurs transiently during unperturbed mitosis.
Mitotic phosphorylation of MST2 does not affect its kinase activity or Hippo-YAP signaling.
We further showed that mitotic phosphorylation-deficient mutant MST2-S385A possesses
higher activity in suppressing cell proliferation and anchorage-independent growth in vitro
and tumorigenesis in vivo. Together, our findings reveal a novel layer of regulation for
MST2 in mitosis and its role in tumorigenesis.

38
2.1.

Introduction

Mammalian sterile 20-like kinase 1/2 (MST1/2) are protein kinases that belong to the
serine/threonine kinase family (MST1 and MST2 are also called STK4 and STK3,
respectively). MST1/2 are the core components of the Hippo pathway and transduce their
kinase activity mainly through directly phosphorylating large tumor suppressor 1/2
(LATS1/2) [2, 5]. Once phosphorylated and activated, LATS1/2 subsequently
phosphorylate and inhibit the downstream effectors Yes-associated protein (YAP) and
transcriptional co-activator with PDZ binding domain (TAZ) [2, 5, 6, 8]. Neither MST1 nor
MST2 alone is required for embryonic development, but double knock out of MST1/2 mice
exhibit early embryonic lethality, suggesting a redundant and overlapping function
between MST1 and MST2 [53]. Recent studies using conditional MST1/2 knockout animal
models demonstrated that MST1/2 function as tumor suppressors [53-56]. In addition to
their role as tumor suppressors in the Hippo signaling pathway, MST1/2 also
phosphorylate several other proteins to exercise their functions in various cellular
processes, mainly in cell proliferation and apoptosis [57].
Mitotic aberration-induced genomic or chromosome instability is characteristic of
human malignancy [44, 58]. Several recent studies have shown that MST1/2 are important
regulators for the mitotic machinery. MST1 phosphorylates and inhibits Aurora B kinase
activity and is required for accurate kinetochore-microtubule attachment [59]. PLK1 (Pololike kinase 1) directly phosphorylates MST2 (possibly MST1 as well) in mitosis and this
phosphorylation allows Nek2A kinase activity to promote centrosome disjunction [60].
These studies suggest that MST1/2 function as tumor suppressors through dysregulation
of mitosis.
We have recently shown that several upstream regulators (KIBRA and Ajuba) [30, 31,
61] and downstream effectors (YAP and TAZ) [12, 13] of the Hippo pathway are
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phosphorylated during mitosis. During these previous studies, we found that the Hippo
core kinase MST2 is also phosphorylated during antimitotic drug-induced G2/M phase
arrest. In this report, we further characterized the phospho-regulation of MST2 in mitosis
and examined the functional significance of the phosphorylation. Our data showed that
mitotic phosphorylation inhibits MST2 tumor suppressing activity.
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2.2.

Materials and Methods

2.2.1. Expression constructs, cell culture and transfection
Flag-MST2 has been described [32]. Point mutations were generated by the
QuikChange Site-Directed PCR Mutagenesis Kit (Stratagene) and verified by sequencing.
HEK293T, HEK293GP, and HeLa cell lines were purchased from American Type Culture
Collection (ATCC) and cultured as ATCC instructed. Attractene (Qiagen) was used for
transient overexpression of proteins in HEK293T and HEK293GP cells following the
manufacturer's instructions. SiRNA oligos were purchased from Dharmacon (the target
sequences

were:

siMST2-1:

CCACAAGCACGA

TGAGTGA;

siMST2-2:

GCCCATATGTTGTAAAGTA; siMST2-3: GAACTTTGGTCCGATGATT) and transfected
with HiPerfect reagent from Qiagen (at the final concentration of 40 nM). Transient
transfections were done with Attractene reagent (Qiagen) following the manufacturer's
instructions. Nocodazole (100 ng/ml for 16h) and Taxol (100nM for 16h) (Selleck
Chemicals) were used to arrest cells in G2/M phase. VX680 (Aurora-A,-B, -C inhibitor),
BI2536 (PLK1 inhibitor), Purvalanol A (CDK1/2/5 inhibitor), SB216763 (GSK-3 inhibitor)
and MK2206 (Akt inhibitor) were also from Selleck Chemicals. RO3306 (CDK1 inhibitor)
was from ENZO Life Sciences. Kinase inhibitors for MEK-ERK (U0126) and p38
(SB203580) were from LC Laboratory. All other chemicals were either from Sigma or
Thermo Fisher.
2.2.2. Tet-On-inducible expression system
The MST2 or MST2-S385A mutated cDNA was cloned into the Tet-All vector [36] to
generate Tet-On-inducible overexpression constructs. Retrovirus packaging, infection,
and subsequent selection were done as we have described previously [62]. The
transduced cells were selected with neomycin (G418) (400 μg/ml) to establish pooled cell
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lines. Cells were maintained in medium containing Tet system-approved fetal bovine
serum (Clontech Laboratories).
2.2.3. Recombinant protein purification and in vitro kinase assay
GST-tagged MST2 or MST2-S385A (cloned in pGEX-5X-1) was bacterially expressed
and purified on GSTrap FF affinity columns (GE Healthcare) following the manufacturer's
instructions. GST-MST2 (1 μg) was incubated with 5–10 U recombinant CDK1/cyclin B
complex ( New England Biolabs ) or 50-100 ng CDK1/cyclin B (SignalChem) in kinase
buffer (New England Biolabs) in the presence of 5 μCi γ-

32P-ATP

(3000 Ci/mmol,

PerkinElmer ) as we previously described [15]. Active CDK2, CDK5, p38, JNK1, JNK2,
MEK1, ERK1, and PLK1 kinases were also purchased from SignalChem.
2.2.4. Antibodies
Rabbit polyclonal phospho-specific antibodies against human MST2 S385 were
generated and purified by AbMart. The peptide used for immunizing rabbits was KRNATpS-PQVQR. The corresponding non-phosphorylated peptide was also synthesized and
used for antibody purification. Anti-β-actin (SC-47778) and anti-cyclin B (SC-752)
antibodies were from Santa Cruz Biotechnology. Glutathione S-transferase (GST) (A190122A), Mst1 (A300-465A), Mst2 (A300-467A), and Lats1 (A300-478A) antibodies were
from Bethyl Laboratories. MST2 antibodies from Cell Signaling Technology (3952) were
also used. Phospho-Histone H3 Ser10 (3377), phospho- YAP Ser127 (4911), phosphoLats1 Ser909 (9157), phospho-Lats1 Ser1079 (8654), Phospho-MST1(Thr183)/MST2(Thr180)
(3681), and cleaved caspase 3 (9664) antibodies were also from Cell Signaling
Technology. Anti-PLK1 antibodies were from Biolegend (667701).Phospho-T210 PLK1
antibodies were purchased from BD Bioscience (558400).
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2.2.5. Phos-tag and Western blot analysis
Phos-tag™ was obtained from Wako Pure Chemical Industries, Ltd. (304-93521) and
used at 20 μM (with 100 μM MnCl2) in 8% SDS-polyacrylamide gels as we previously
described [61]. Western blotting, immunoprecipitation, and lambda phosphatase
treatment assays were done as previously described [31, 34].
2.2.6. Cell proliferation and colony formation assays
For cell proliferation assays, cells (50,000/well) were seeded in a 6-well plate in
triplicate. Cells were counted by a hemacytometer. Colony formation assays in soft agar
were performed as described [32]. Cells (5000/well) were seeded in a 6-well plate and
colonies were counted by ImageJ online.
2.2.7. Animal studies analysis
For in vivo xenograft studies, 2.0 X 106 HeLa cells expressing Tet-All-MST2 or Tet-AllMST2-S385A (non-phosphorylatable mutant) were subcutaneously injected into flanks
(both left and right) of 6-week-old male athymic Ncr-nu/nu nude mice (Harlan). Five
animals were used per group. Tumor sizes were measured every four days using an
electronic caliper starting at 10 days after injection. Tumor volume (V) was calculated by
the formula: V = 0.5 X length X width2 [32]. The animals were housed in pathogen-free
facilities. All animal experiments were approved by the University of Nebraska Medical
Center Institutional Animal Care and Use Committee.
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2.2.8. Statistical analysis
Statistical significance was analyzed using a two-tailed, unpaired Student's t-test.
Pearson Chi-Square analysis was used to determine the statistical significance in Fig. 26C.
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2.3.

Results

2.3.1. MST2 is phosphorylated during antimitotic drug-induced G2/M arrest
Using a Phos-tag SDS-polyacrylamide gel system, we recently examined the
phosphorylation status of the Hippo pathway proteins during G2/M arrest induced by Taxol
or Nocodazole. During these experiments, we found that MST2, but not MST1, was
upshifted on a SDS-polyacrylamide gel during G2/M arrest (Fig. 2-1A, B) [61]. Lambda
phosphatase treatment largely abolished the mobility upshift of MST2, suggesting that
MST2 is phosphorylated during G2/M arrest (Fig. 2-1A). The phosphorylation on Thr183MST1 (Thr180-MST2) in the activation loop was not altered under these conditions (Fig. 21B).
2.3.2. Identification of the corresponding kinase for MST2 phosphorylation
We used various kinase inhibitors to identify the candidate kinase for MST2
phosphorylation. Inhibition of p38 kinase (with SB203580), JNK1/2 (with SP600125),
MEK-ERK (with U0126), Akt (with MK-2206), PLK1 (with BI2536), Aurora-A, -B, -C (with
VX680) or GSK-3 (with SB216763) failed to alter the mobility/phosphorylation of MST2
during G2/M arrest (Fig. 2-1C, lanes 5-11). These inhibitors are effective under the
conditions used [12, 63]. Interestingly, treatments with RO3306 (CDK1 inhibitor) or
Purvalanol

A

(CDK1/2/5

inhibitor)

almost

completely

reverted

the

mobility

shift/phosphorylation (Fig. 2-1C, lanes 3-4). These data suggest that CDK1 is likely the
corresponding kinase for MST2 phosphorylation induced by Taxol or Nocodazole
treatment.
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2.3.3. CDK1 phosphorylates MST2 in vitro
Next, we performed in vitro kinase assays with bacterially purified MST2 proteins as
substrates to determine which kinase can directly phosphorylate MST2. Fig. 2-2A shows
that purified CDK1/cyclin B kinase complex robustly phosphorylated GST-MST2 proteins
in vitro (Fig. 2-2A). No or very mild phosphorylation was detected when CDK2, CDK5,
p38, JNK1, JNK2, MEK1, or ERK1 kinase was used in these assays, though these kinases
recognize the same consensus sequence as CDK1 kinase. These results indicate that
CDK1 specifically and directly phosphorylates MST2 in vitro.
2.3.4. CDK1/cyclin B complex phosphorylates MST2 at S385 in vitro
CDK1 phosphorylates substrates at a minimal proline-directed consensus sequence
[40]. MST2 only contains a total of 2 S/TP motifs (Ser107 and Ser385) and Ser107 also exists
in MST1. Therefore, Ser385 was chosen for further investigation. Interestingly, mutating
Ser385 to alanine completely abolished the

32P

incorporation in GST-MST2, suggesting

that Ser385 is the main CDK1 site in MST2 in vitro (Fig. 2-2B). A recent report showed that
MST2 is also phosphorylated by the mitotic kinase PLK1 [60]. Consistent with that study,
we confirmed that MST2 is also a suitable substrate for PLK1 (Fig. 2-2C); however,
mutating Ser385 to alanine failed to significantly reduce the phosphorylation of MST2
mediated by PLK1 (Fig. 2-2C). These observations suggest that PLK1 and CDK1
phosphorylate different sites in MST2 in vitro.
We have generated phospho-specific antibodies against Ser385. In vitro kinase assays
confirmed that CDK1 readily phosphorylates MST2 at Ser385 (Fig. 2-2D). Mutating Ser385
to alanine abolished the phosphorylation, confirming the specificity of our antibody (Fig.
2-2D). These data indicate that CDK1 phosphorylates MST2 at Ser385 in vitro.
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2.3.5. CDK1 phosphorylates MST2 at S385 in cells
Next, we explored whether this phosphorylation occurs in cells. Taxol treatment
significantly increased the phosphorylation of MST2 Ser385 (Fig. 2-3A). Addition of
RO3306 or Purvalanol A, but not the PLK1 kinase inhibitor BI2536, greatly inhibited MST2
Ser385 phosphorylation, suggesting that these antibodies specifically recognize
phosphorylated MST2 and that phosphorylation of MST2 Ser385 is CDK1 kinase
dependent (Fig. 2-3A). As expected, the signal of MST2 Ser385 was significantly reduced
in MST2 knockdown cells (Fig. 2-3B). Using immunoprecipitated samples, we further
demonstrated that MST2 is phosphorylated on Ser385 during Taxol-induced G2/M in a
CDK1-dependent manner (Fig. 2-3C).
2.3.6. MST2 phosphorylation on Ser385 occurs during normal mitosis
To determine whether phosphorylation of MST2 Ser385 occurs during normal mitosis,
a double thymidine block and release method was used [38]. Fig. 2-3D shows that the pMST2 S385 signal was significantly increased in cells after 11 h of being released from
double thymidine block (Fig. 2-3D). A significant portion of cells is in mitosis, as revealed
by increased cyclin B levels (Fig. 2-3D). These results indicate that the phosphorylation of
MST2 S385 occurs dynamically during normal mitosis.
2.3.7. Mitotic phosphorylation of MST2 does not impact Hippo-YAP activity
MST2 is a core kinase in the Hippo-YAP signaling. We first tested whether this
phosphorylation affects its kinase activity. The non-phosphorylatable (MST2-S385A)
mutant has similar basal kinase activity revealed by phosphorylation at T180 as wild type
MST2 (Fig. 2-4A), suggesting that S385 phosphorylation of MST2 does not impact its
kinase activity. As expected, YAP S127 (a major phosphorylation site mediated by
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LATS1/2

kinases)

phosphorylation

was

significantly

increased

upon

MST2

overexpression [32, 62]. However, ectopic expression of MST2-S385A had similar effects
as wild type MST2 on YAP S127 phosphorylation (Fig. 2-4B). We further established
doxycycline-induced MST2 or MST2-S385A in HeLa cells, and in the presence of
doxycycline, both wild type MST2 and MST-S385A were modestly induced at a similar
level (Fig. 2-4C). No significant changes were detected in the Hippo-YAP signaling activity
under these conditions (Fig. 2-4C). These observations suggest that phosphorylation of
MST2 at S385 does not affect Hippo-YAP activity.
2.3.8. The non-phosphorylatable mutant MST2 possesses stronger inhibitory
activity in cell proliferation and anchorage-independent growth
Next, we compared the effects from doxycycline-induced MST2- or MST2-S385Aexpressing HeLa cells to determine the biological significance of S385 phosphorylation of
MST2. Interestingly, overexpression of the MST2-S385A mutant significantly reduced cell
proliferation when compared to MST2-expressing cells (Fig. 2-5A). Furthermore, MST2S385A-expressing cells formed a significantly lower number of colonies in soft agar when
compared with MST2-expressing cells (Fig. 2-5B, C). These data suggest that mitotic
phosphorylation inhibits MST2 activity in suppressing cell proliferation and anchorageindependent growth.
2.3.9. The non-phosphorylatable MST2 mutant inhibits tumorigenesis in vivo
We further evaluated the influence of S385 phosphorylation on tumor growth in
animals. An equal number of HeLa cells expressing MST2 or MST2-S385A were
subcutaneously inoculated into immunodeficient mice and tumor size was monitored in
the presence of doxycycline. Interestingly, in line with the results in Fig. 2-5, tumors from
mice bearing MST2-S385A-expressing cells were significantly smaller when compared
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with those from mice injected with wild type MST2- expressing cells (Fig. 2-6A, B).
Western blotting analysis showed that MST2 (wild type or S385A) expression levels were
similar in most of these tumors (Fig. 2-6C). Interestingly, expression of MST2-S385A
induced stronger apoptosis (detected by cleaved caspase 3) when compared with wild
type MST2 (Fig. 2-6C, Pearson Chi-Square test, p<0.1). These results suggest that
phosphorylation of MST2 at S385 inhibits its tumor suppressing activity in vivo.
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2.4.

Discussion

In the current study, we identified a novel phosphorylation site (S385) on MST2 that is
dynamically/transiently

phosphorylated

by

CDK1

during

mitosis.

The

mitotic

phosphorylation of MST2 inhibits its tumor suppressing activity without affecting its own
kinase activity and the Hippo-YAP signaling. Together, we provided a novel layer of
regulation of MST2 activity in cancer cells.
MST2 along with WW45 plays a pivotal role in centrosome disjunction. They directly
interact with NIMA-related kinase Nek2A and recruit it to the centrosome [45]. Specifically,
MST2 phosphorylates Nek2A and consequently promotes its recruitments to the
centrosome. Further, the MST2-WW45 complex contributes to the phosphorylation of the
c-Nap1 and Rootletin (two centrosomal linker proteins) which are major Nek2A
phosphorylation targets and bridge the gap between the two centrosomes. Interestingly,
other Hippo pathway components, such as LATS1/2, Rassf1A and YAP are dispensable
for Nek2A recruitment [45]. Those phenotypes are compatible with MST2 S385
phosphorylation. They affect mitosis without impacting Hippo-YAP activity. Whether S385
phosphorylation of MST2 is involved in this process is still unknown.
On the other hand, down regulation of MST2 causes chromosome misalignment
mediated by Aurora B [59]. Besides, MST2 cooperates with its activator, Mob2 and a
scaffold protein, Furry, to contribute to mitotic activation of NDR1 kinase, thereby
regulating the precise alignment of mitotic chromosomes [64].
Taken together, MST2 is essential in centrosome regulation and chromosome
alignment in mitosis. Future studies are needed to further determine whether S385
phosphorylation of MST2 contributes to the fidelity of mitosis and how this phosphorylation
links subsequent tumorigenesis. Our results showed that mitotic phosphorylation of MST2
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S385 does not impact the LATS and YAP activity and thus, it will be interesting to see
what the downstream effector of S385 phosphorylation is.
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Figure 2-1. CDK1-dependentphosphorylation of MST2 duringG2/M arrest.
(A) HeLa cells were treated with Taxol as indicated and cell lysates were further treated
with (+) or without (-) λ phosphatase (ppase). Total cell lysates were probed with antiMST2 antibody on Phos-tag SDS-polyacrylamide gels. (B) HeLa cells were treated with
DMSO, Taxol or Nocodazole (Noco). Total cell lysates were probed with the indicated
antibodies on Phos-tag or regular SDS-polyacrylamidegels. (C) HeLa cells were treated
with Taxol together with or without various kinase inhibitors as indicated. RO3306 ( CDK1
inhibitor, 5μM ), Purvalanol A ( CDK1/2/5 inhibitor, 10 μM ), SB203580 ( p38 inhibitor, 10
μM ), SP600125 ( JNK1/2 inhibitor, 20μM ), U0126 ( MEK-ERK inhibitor, 20 μM ), MK2206
( AKT inhibitor, 10 μM ), BI2536 ( PLK1 inhibitor, 100 nM ), VX680 (Aurora-A, B, C
inhibitor, 2 μM), and SB216763 (GSK3 inhibitor, 10 μM ) were used. Inhibitors were added
1-2h before harvesting the cells (with MG132toprevent cyclin B from degradation and cells
from exiting from mitosis). Total cell lysates were subjected to Western blotting with the
indicated antibodies. SE: short exposure; LE: long exposure.
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Figure 2-2. CDK1 phosphorylates MST2 in vitro.
(A) In vitro kinase assays with kinases as indicated. (B) In vitro kinase assays with
CDK1/cyclin B complex using GST-MST2 or GST-MSTS385A proteins as substrates.
RO3306 (5μM) was used to inhibit CDK1 kinase activity. (C) In vitro kinase assays with
PLK1 kinase using GST-MST2 or GST-MSTS385A proteins as substrates. (D) In vitro
kinase assays were done as in B except anti-p-S385 MST2 antibody was used.
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Figure 2-3. CDK1 mediates the phosphorylation of MST2 S385 in cells.
(A) HeLa cells were treated with Taxol together with or without various kinase inhibitors
as indicated. Inhibitors were added 1.5 h before harvesting the cells (with MG132 to
prevent cyclin B from degradation and cells from exiting from mitosis). Total cell lysates
were subjected to Western blotting with the indicated antibodies. (B) HeLa cells were
transfected with scrambled siRNA (control) or siRNA against MST2 for 48h and were
further treated with (+) or without (-) Taxol for 14h. The total cell lysates were subjected to
Western blotting with the indicated antibodies. (C) MST2 proteins in HeLa cells were
immunoprecipitated and the samples were probed with phospho-S385 MST2 and
subsequent MST2 antibodies. Total lysates before immunoprecipitation were also probed
with the indicated antibodies. CDK1 inhibitors RO3306 (5 μM) or Purvalanol A (10 μM)
together with MG132 (25 μM) were added 1.5 h before the cells were lysed. * marks the
IgG heavy chain. (D) A double thymidine block and release was performed in HeLa cells
and samples were collected at the indicated time points. The total cell lysates were probed
with the indicated antibodies.
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Figure 2-4. Mitotic phosphorylation of MST2 does not affect the Hippo-YAP
activity.
(A) HEK293T cells were transfected with Flag-MST2 or Flag-MST2-S385A as indicated.
The immunoprecipitates (with Flag antibodies) were probed with the indicated antibodies.
* marks the IgG heavy chain. WT: wild type. (B) GFP-YAP was co-transfected with FlagMST2-WT or Flag-MST2-S385A with or without Flag-LATS2. The cells were harvested at
48 h post-transfection and the total cell lysates were analyzed by Western blotting with the
indicated antibodies. (C) Establishment of Tet-On-inducible HeLa cell lines expressing
vector, MST2-WT, or MST2-S385A. Total cell lysates were harvested from these cell lines
in the presence of doxycycline (1 μg/ml for 2 days) and were subjected to Western blotting
analysis.
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Figure 2-5. MST2-S385A suppresses cell proliferation and anchorage-independent
growth.
(A) Cell proliferation assays with HeLa cells-expressing Tet-MST2-WT or Tet-MST2S385A. Cells were kept on Tet-approved FBS and doxycycline was added (1 μg/ml) to the
cells 2 days prior to the experiments. Data were expressed as the mean ± s.d. of three
independent experiments. **: p < 0.01; *: p < 0.05 (t-test). (B, C) Colony assays in soft
agar to assess anchorage-independent growth of HeLa cells expressing Tet-MST2-WT or
Tet-MST2-S385A in the presence of doxycycline. Data were expressed as the mean ±
s.d. of three repeats (B) and representative images were shown (C). **: p < 0.01 (t-test).
WT: wild type.
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Figure 2-6. MST2-S385A suppresses tumorigenesis in mice.
(A) Tumor growth curve. HeLa cells expressing Tet-MST2-WT or Tet-MST2-S385A were
subcutaneously inoculated into athymic nude mice (n = 5, on both left and right flanks)
and the mice were kept on doxycycline (0.5 mg/ml)-containing water throughout the
experiments. One inoculation (left flank) in the wild type group did not form visible tumor
and was excluded from the analysis. Therefore, the tumor volume at each point was the
average of 9 (MST2-WT) or 10 (MST2-S385A) tumors. **: p< 0.01; *: p < 0.05 (t-test). (B)
The tumors in each group were excised and photographed at the endpoint. (C) Western
blotting analysis with tumor samples from B. Pearson Chi-Square test showed that it was
marginally significant between two groups (p < 0.1).wild type.
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CHAPTER 3: ROLE OF YAP IN PANCREATIC CANCER-ASSOCIATED
CACHEXIA
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ABSTRACT
Cachexia is a wasting syndrome characterized by body weight loss, atrophy of white
adipose tissue, and systemic inflammation. It frequently occurs in patients of infectious
diseases, such as AIDS and tuberculosis, or chronic disease, like heart failure, pulmonary
disease and chronic kidney disease. Most commonly, cachexia is observed in cancer,
termed cancer-associated cachexia (CAC). Pancreatic cancer has one of the highest
incidences

of

cachexia

compared to

other

cancer

types.

Pancreatic

ductal

adenocarcinoma (PDAC), is one of the devastating diseases that causes a high death rate
worldwide. Last decade, the Hippo-YAP signaling pathway was discovered and identified
as a tumor suppressor pathway, via controlling cell proliferation and apoptosis. Recent
studies indicate that Hippo-YAP signaling plays a critical role in the development of
pancreatic cancer. However, the underlying mechanism is poorly understood and
furthermore, little is known whether YAP is involved in pancreatic CAC. To address these
important questions, we generated a doxycycline-inducible mouse model in which active
YAP was specifically expressed in the pancreas to explore the role of YAP and underlying
mechanisms in the development of pancreatic CAC. We observed that pancreatic specific
activation of YAP in mice leads to pancreatic acinar-to-ductal metaplasia (ADM) in two
weeks. Moreover, significant body weight loss and food intake decrease were observed
after YAP induction in the pancreas. Further, we showed that the level of CXCL13 was
increased in serum of YAP-pancreas mouse model. Thus, our study suggests a potential
role of the YAP-CXCL13 axis in pancreatic CAC.
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3.1.

Introduction

It is estimated that half of cancer patients develop cachexia syndrome at their late
stage with a severe loss of adipose tissue and skeletal muscle mass [65]. Cachexia is
characterized by body weight loss, atrophy of white adipose tissue, and systemic
inflammation. Limited treatment is currently available for cancer-associated cachexia
(CAC), which leads to approximately 20% of total deaths in cancer patients [66].
Therefore, new therapeutic targets for CAC prevention and treatment are urgently needed.
In the past decades, the investigators have searched for potential mediators of CAC
in hoping to develop therapeutic strategies against tumor induced weight loss and muscle
atrophy. The loss of body fat seems to arise from the increased lipolysis, not the decreases
of lipogenesis. This idea was confirmed by the result of elevated level of free fatty acids
(FFA) and glycerol in cachexia cancer patient plasma, even presented before significant
weight loss [67]. In addition to lipolysis increase, there is a well-established link between
cachexia and systematic inflammation. Interleukin 6 (IL-6) acts alone, or correlated with
other cytokines, as a driver of systematic inflammation in CAC [68]. Circulating levels of
IL-6 have been shown to correlate with weight loss, as well as survival in cancer patients
[69]. In an IL-6-proficent murine synergetic model of cachexia, the silencing of IL-6 could
rescue the cachexia phenotype, including the reduction of loss of fat tissue and
morphology change of adipose tissue. The anti-IL-6 antibody treatment can protect K5SOS cachexia mice model from losing fat, but recent clinical trials of a monoclonal antiIL-6 antibody in weight-losing lung cancer patients have no significant effect on loss of
body mass [70, 71]. However, the antibody treatment on patients showed reversal of
anorexia, fatigue, and anemia [72]. Therefore, additional potential targets for CAC
treatment is urgently needed. What these targets are and how they contribute to CAC are
critical subjects for current investigation.
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Cachexia is associated with multiple type of cancers, particularly the gastrointestinal
tract cancer and the lung cancer [73]. Among those cancer types, PDAC has the highest
incidence of cancer cachexia and patients experience the greatest degree of weight loss
and shorter survival time [74]. Pancreatic intraepithelial neoplasia (PanIN) is responsible
for the development of pancreatic cancer. The origin of the duct cell in the PanIN-PDAC
progression model is compatible with the concept of acinar to ductal metaplasia (ADM)
preceding the generation of the small ducts [75].
The Hippo-YAP signaling pathway was originally discovered in Drosophila and plays
an important role in tumorigenesis by regulating cell proliferation and apoptosis [2]. Later
studies showed that this pathway is highly conserved in mammals [76, 77]. The classic
pathway in mammals consists of a series of kinases cascade. The core components of
the Hippo pathway contain kinases MST1/2 (mammalian sterile-20 like kinases1/2) and
LATS1/2 (large tumor suppressor 1/2), with two scaffold proteins Sav (Protein Salvador
Homolog 1) and Mob1 (Mps one binder 1). MST1/2 directly phosphorylates LATS1/2 to
activate LATS1/2, which subsequently phosphorylate and inhibit the downstream effector
YAP (yes-associated protein) and TAZ (transcriptional co-activator with PDZ binding
domain). Without the inhibition of Hippo signaling, YAP/TAZ can translocate from
cytoplasm to nucleus. After binding with transcription factors, transcription of target genes
will be induced to promote cell proliferation and inhibit apoptosis [7]. Studies from mouse
models and cancer patients confirmed/demonstrated the oncogenic role of YAP in
tumorigenesis. For example, overexpression of YAP specifically in liver is sufficient to
promote hepatocellular carcinoma within three months [32]. Half of aged prostate-specific
YAP transgenic mice are able to develop prostate tumors compared with no tumor formed
in the wildtype control [78]. These mouse model studies suggest that YAP plays an
important role in cancer development.
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Recent studies suggested that YAP also plays significant role in the development of
pancreatic cancer. In our previous study, upregulation of YAP in pancreatic cells can
promote pancreatic cancer cell migration and invasion in vitro [79]. Additionally,
hyperactive YAP in pancreatic cell not only promotes anchorage-independent growth in
vitro, but also drives tumorigenesis in xenograft mice [79]. Furthermore, Kapoor et al.
showed that YAP activation can maintain tumor growth in Kras (G12D)-driven PDAC
model upon KRAS extinction [80]. These lines of evidence indicate that the transcriptional
co-activator YAP plays an important role in pancreatic cancer development. We further
explore the role of YAP in PDAC by generating intact transgenic animals, which was the
first transgenic animal model expressing hyperactive YAP specifically in pancreas. Our
study showed that the YAP-pancreas mouse not only initiated ADM, but also caused
severe weight loss and food intake reduction. Further, we observed highly elevated serum
level of CXCL13 in YAP-pancreas mouse, indicating the potential role of this cytokine in
cachexia development.
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3.2.

Materials and Methods

3.2.1. Generation of mouse strains
Genetically engineered mouse strains TetO-YAPS127A [81], Ptf1α-Cre (Mutant Mouse
Resource & Research Centers) and Rosa-LSL-rtTA (Jackson Lab) were interbred to
generate all experimental colonies (Fig 3-1). All the experimental animals were maintained
on mixed background in pathogen-free conditions at University of Nebraska Medical
Center (UNMC). Mice were fed with doxycycline water (Doxycycline Hyclate, SigmaAldrich D9891, 0.2mg/ml in 25mg/ml sucrose) to induce active YAP expression specifically
in pancreas. All manipulations were approved under UNMC Institutional Animal Care and
Use Committee (IACUC) under protocol number 12-044.
3.2.2. Cachexia phenotype observation/measurement
Each group (control and YAP transgenic) has equal amount (n=3) of mice which were
housed in the cage with same size. Total body weight was measured at time point of 1
week and 8 weeks after Dox induction. For Food intake measurements, equal amount of
food tablets was dispensed to each group at the beginning of the designed week. The
weight of given food tablets were measured same time everyday within the designed week.
Average food intake of each mice within the week were calculated.
3.2.3. Immunohistochemistry (IHC) Staining
Tissues were fixed in 4% formalin overnight and embedded in paraffin. The unstained
slides were deparaffinized in xylene and hydrated gradually. The hydrated slides were
treated with standard citrate or tris-EDTA retrieval buffer for 30 min at 95°C.

After

incubation overnight with the primary antibodies at 4°C, the slides were incubated with
biotinylated secondary antibodies (VECTASTAIN Elite ABC HRP Kit, PK-6100, Vector
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Laboratories Ltd.) for 30 min at room temperature. Antibody labeling was visualized with
a DAB kit follow the manufacturer’s instructions (ImmPACT DAB Peroxidase HRP
Substrate, Vector Laboratories Ltd). The antibodies used for IHC analyses are shown
below. YAP (1:1000 dilution, 4912), Keratin 17/19 (1:200 dilution, 12434), and α-Amylase
(1:300 dilution, 3796) were from Cell Signaling Technology. Ki67 (1:400 dilution, PA516785) is from Thermo Fisher.
3.2.4. Analysis of secreted cytokines and CXCL13 ELISA measurements
The mouse blood samples were collected at designed time point. Samples clotted for 2
hours at room temperature before centrifuging for 20 minutes at 2000 x g. Serum were
collected for assay immediately or aliquoted and stored at -80°C. Avoid repeated freezethaw cycles. Semiquantitative cytokine detection was performed using Proteome Profiler
Antibody Arrays for 111 different antibodies (R&D system; ARY028) according to
manufacturer’s instructions. The CXCL13 level was measured using mouse CXCL13
ELISA kits (R&D system; MCX130) [71].
3.2.5. Statistical analysis
Data were analyzed via two-tailed and unpaired Student’s t test or ANOVA. P < 0.05
was considered statistically significant.
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3.3.

Results

3.3.1. YAP is sufficient to promote ADM in YAP-pancreas model.
Previous studies have demonstrated in immunodeficiency mice that YAP gain-offunction can promote pancreatic cancer cell tumorigenesis [79]. However, there is no
transgenic mouse model available to further explore the role of YAP in pancreatic cancer.
To determine whether YAP is involved in PDAC oncogenesis, we obtained the following
mouse strains, TetO-YAPS127A [81], Ptf1α-Cre (Mutant Mouse Resource & Research
Centers) and Rosa-LSL-rtTA (Jackson Lab) from colleagues (Table 1). Using mouse
strains above, for the first time, we established pancreas-specific dox-inducible YAP
overexpression transgenic mouse model (Fig 3-1). PDAC are thought to originate from
mature acinar cells which will transdifferentiate into ductal-like cells, a process known as
acinar to ductal metaplasia (ADM). When YAP-transgenic mice (1-month-old) were
exposed to Dox for 2 weeks, they developed ADM. YAP-overexpressed pancreases were
distinguishable from wild-type pancreas in overall histology by hematoxylin and eosin
(H&E), major pancreatic cell lineage markers [including amylase (in acinar cells),
cytokeratin 19 (CK19; in ductal cell)], and the proliferation marker (Ki67). Generally, the
H&E staining indicates that most area of wild-type pancreas have normal acinar cell
presented, while the examination of pancreatic tissues from young YAP-pancreas
transgenic mice showed abnormal cell morphology (Fig 3-2A). Further, the IHC staining
showed that YAP overexpression pancreas significantly increased duct-like area (CK19+)
but have fewer acinar cell area (α-Amylase+) compared with wild-type pancreas (Fig 32B). Additionally, those ductal-like area of YAP-pancreas transgenic mice showed high
level of YAP and Ki67 expression, indicating that YAP activation promoted cell proliferation
and ADM in pancreas. (Fig 3-2A). Comparing the size and texture of pancreas in control
and transgenic mice, the pancreases from the transgenic group were enlarged and of
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elastic, hard consistency (Fig 3-2C). Those observations indicate that the acinar cells have
been transdifferentiated into ductal-like cells in YAP-pancreas transgenic mice. These
results suggest that the specific expression of YAP in pancreas initiates the process of
ADM, which can finally develop to PDAC.
3.3.2. The YAP-pancreas model has cachectic phenotype.
Cachexia is a wasting syndrome characterized by body weight loss, atrophy of white
adipose tissue, and systemic inflammation [67, 72, 82]. Besides the ADM, we also
observed cachectic phenotype on the YAP-Pancreas model. After being exposed to dox
for 8 weeks, the 3-month-old YAP-pancreas transgenic model displayed a loss of 15% to
30% of total body weight (Fig 3-3A). Food intake was decreased in both female and male
transgenic mice, (Fig 3-3B, 3C). At necropsy, YAP-pancreas model exhibited massive fat
atrophy, as evidenced by almost complete loss of gonadal fat (Fig 3-3D). Histological
examination of gonadal fat revealed the presence of abundant islets composed of small
adipocytes with big nuclei and multilocular cytoplasm (Fig 3-3E). These data indicate that
YAP overexpression in pancreas has the potential to promote CAC.
3.3.3. Association between YAP and CXCL13 in pancreatic CAC.
Serum levels of many cytokines and their soluble receptors are manipulated in diverse
cancer types [83]. The mutual effect between cancer cell and its microenvironment can
induce further production and release of cytokines. Several cytokines including TNF–α,
IL-6 have been reported in facilitating a cachectic state [83, 84]. According to known
characteristics of CAC and our results, we expect that high level of YAP in pancreas tumor
will stimulate the induction of tumor-derived cytokines (tumorkines). Proteome Profiler
Mouse Cytokine Array Kit (R&D) was applied to detect the level of 111 cytokines with
single plasma sample (Fig 3-4A). We found that the level of several cytokines
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(CCL17/TARC 2, CHI3L1 , CXCL13, CXCL16 , LDL R , Lipocalin-2/NGAL, Pentraxin
2/SAP 2 and Pentraxin 3/TSG-14) were significantly elevated after YAP induction (Fig 34A, 4B). Further, we examined the serum level of CXCL13 in YAP-pancreas model and
control mice with both 1 week and 1 month dox induction via CXCL13 ELISA kit. The
upregulation of CXCL13 in the YAP-pancreas model was confirmed (Fig 3-4C).
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3.4.

Discussion

Recent studies demonstrated that YAP gain-of-function promotes pancreatic cancer
cell tumorigenesis in vitro and in vivo (both subcutaneously and orthotopically) [79, 80].
We then established genetically engineered mouse model of pancreas-specific YAP
overexpression. In this study, the genetic mouse model we generated displayed ADM and
cachectic phenotype (Fig 3-2, 3). We further identified the high level cytokine, CXCL13, in
the mouse model serum via cytokine array (Fig 3-4). The role of CXCL13 in pancreatic
cancer and cachexia will be determined in future study.
CXCL13 is a small cytokine belonging to the CXC chemokine family, also known as B
cell-attracting chemokine 1 (BCA-1). It is expressed by stromal cells within B-cell follicles
in secondary lymphoid tissues [85]. Tumor-infiltrating lymphocyte B cells have been
reported to be prevalent in human pancreatic cancer tissues [86]. B cell infiltration was
detected by Pylayeva-Gupta et al in human PanIN and Kras-driven pancreatic cancer
model [87].

This group further showed implanted pancreatic ductal epithelial cells

expressing oncogenic KrasG12D into wild-type pancreata induced B cells accumulation
in the regions of neoplastic lesions. Besides, the implantation using mice lacking B cells
(μMT mice) had reduced tumor growth compared with tumors grown in wild-type mice.
Meanwhile, the anti-CXCL13 treatment can also reduce tumors grown in implantation [87].
These studies identified a B-cell subset that infiltrates into pancreas during early neoplasia
and is essential for pancreatic tumorigenesis.
To date, the role of Tumor-infiltrating lymphocytic B cells (TIL-Bs) in PDAC has not
been widely investigated. Based on recent publications, the infiltration of B cell supports
pancreatic tumorigenesis through multiple mechanisms, including suppression of other
immune cells in the tumor microenvironment and promoting pancreatic cancer cell
proliferation. Inhibition of B-cell infiltration into the tumor, inhibition of B-cell activity, or
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simple depletion of B cells using a specific mAb significantly reduced tumor progression
[71, 86]. A clinical study showed that the serum level of B cell-activating factors in
pancreatic cancer patients is associated with survival, and maturation of B cells was
significantly higher in pancreatic cancer patients than in healthy subjects [88].
The Hippo-YAP signaling pathway was originally discovered in Drosophila and plays
an important role in tumorigenesis by regulating cell proliferation and apoptosis [2]. Both
in vitro cell study and in vivo immunodeficiency mice study showed that the loss of
LATS1/2 promoted cell proliferation and tumor survival. However, the loss of LATS1/2
suppressed tumor growth in animal with intact immune system which demonstrates its
ability to stimulate an immune response leading to the destroying of cancer cells [89].
However, Guo et al reported later that activation of YAP in tumor-initiating cells (TICs)
recruits macrophage to small foci of altered hepatocytes. The recruitment is mediated by
secreted chemokine CCL2 and growth factor CSF1 induced by YAP-TEAD transcriptional
complex. Elimination of TIC-associated macrophages (TICAMs) impede tumorigenesis
[90]. Interestingly, YAP mediates myeloid-derived suppressor cells (MDSC) infiltrating to
prostate tumor via activation of CXCL5-CXCR2 signaling. The infiltrated MDSC promotes
prostate tumor progression [91]. The role of Hippo pathway in cancer immune is still under
debate. Based on published discoveries, the activation of its downstream effector YAP or
knock-out of its upstream kinase will induce immune response via different mechanisms
depending on experimental models. Meanwhile, the activity of YAP was recently reported
to be regulated by metabolic pathways, such as aerobic glycolysis and mevalonate
synthesis [10, 92, 93]. In the meantime, YAP can reprogram metabolism to enable liver
growth [93]. Those discoveries demonstrated an indispensable role of YAP in metabolism
regulation which is a key step in cachexia development.
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However, the dysregulation of metabolism can perturb host immune to control cancer
development. Several studies have demonstrated that glucose utilization of TILs may be
impaired by glycolytic activities of cancer cells [94, 95]. Moreover, glucose is a critical
substrate for T lymphocytes [96]. The demand for glucose supply is altered when Naïve T
cell differentiates into effector T cells, which rely on a high intake of glucose to support
proliferation and effector functions, such as cytotoxicity and cytokine production [97]. The
role of CXCL13 in the network of YAP, cancer immune and cachexia is poorly understood.
We speculate that the secreted CXCL13 in the YAP-pancreas model may induce immune
cell infiltration to pancreatic microenvironment leading the initiation of pancreatic cancer
as well as pre-cachexia. Future studies will be focusing on two aspects. Firstly, we will
determine whether CXCL13 is a direct target of YAP. Secondly, how CXCL13 affects
pancreas microenvironment and its role in pancreatic CAC will be determined. Unveiling
the underline mechanism will lay a solid foundation in translating a new approach for
immunoprevention in pancreatic CAC.

76
Figure 3-1. Generation of inducible pancreas-specific YAP overexpression.
(A). Schematic representation of approaches in generating transgenic mice. The
pancreas-specific Cre recombinase (Ptf1α-cre) is used to activate reverse tetracycline
controlled transactivator (rtTA) in Rosa-LSL-rtTA knock-in mice. When these 2 mouse
strains are crossed to a tetO-YAPS127A transgenic mice, and when the triple transgenic
mice are subjected to Dox-induction, YAP can be expressed in a Dox-inducible fashion
specific in pancreas. (B). Tetracycline-inducible conditional YAP expression system. Dox
binding to rtTA leads to transcriptional activation of transgene, YAP.
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Figure 3-2. YAP is sufficient for ADM in YAP-Pancreas model.
(A-B) Representative images of H&E, YAP, Ki67, α-Amylase and CK19 IHC staining of
pancreatic sections from 1-month-old control (CTRL, Ptf1а-Cre; Rosa-LSL-rtTA) and YAP
transgenic (YAP-tg, Ptf1а-Cre; Rosa-LSL-rtTA;YAPS127A) with 2 week dox induction. (C)
Representative pancreas image from mice used in (A).
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Figure 3-3. The YAP-Pancreas model has cachectic phenotype.
(A)Total body weight in YAP-pancreatic model and corresponding littermate controls of
male and female (dox induction at 3-months age, n =3 per genotype) at the time point of
8 weeks after dox induction. (B-C) Food intake of mice used in (A). (D) Representative
macroscopic pictures of control mice and YAP-pancreatic model with 2 weeks of dox
induction at 1-month age at autopsy. The arrowheads point to normal left gonadal fat in
control mice. In the YAP-pancreatic model, left gonadal fat (arrowhead) is almost
completely absent. (E)Representative images of hematoxylin and eosin (H&E) staining of
gonadal fat in mice from (D).
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Figure 3-4. CXCL13 is induced by YAP overexpression in pancreas.
(A) Proteome Profiler Mouse XL Cytokine Array results. CXCL13 dots are marked in red
box. Other up-regulated factors are marked in blue box. (B) List of upregulated cytokines
identified from (A). (C) ELISA measurements of CXCL13 relative protein level in YAPpancreas mouse model serum.
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Table 1. List of genetic mouse strain source.

Strain symbol

Sources

Ptf1α-Cre
Rosa-LSL-rtTA
TetO-YAP(S127A)

Mutant Mouse Resource & Research Centers
The Jackson Laboratory
Harvard University, Dr. Fernando Carmago
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